自身免疫性溶血性贫血的治疗进展研究  

Research on the Treatment Progress of Autoimmune Hemolytic Anemia

作　　者：梁志东[1] 侯蓓蕾[1] 周咏红[1] 潘秋燕[1] 魏莉萍 Liang Zhidong;Hou Beilei;Zhou Yonghong;Pan Qiuyan;Wei Liping(Liuzhou People’s Hospital,Liuzhou,Guangxi 545006)

机构地区：[1]柳州市人民医院,广西柳州545006

出　　处：《科技与健康》2024年第9期37-40,共4页Technology and Health

基　　金：广西壮族自治区卫生健康委员会自筹经费科研课题“自身免疫性溶血性贫血DAT阳性患者血型鉴定及交叉配血试验研究”(720210419)。

摘　　要：自身免疫性溶血性贫血(autoimmune hemolytic anemia,AIHA)是一种由自身抗体介导的溶血性贫血疾病,机体免疫机制紊乱、调控功能紊乱等,抗体或(和)补体对红细胞膜的作用,使得红细胞遭受破坏,从而引发溶血性贫血。大多数患者对肾上腺激素反应敏感,治疗效果有明显改善。但也有一部分患者因起病急、病情进展快,或对激素耐药性强,整体治疗效果欠佳。对AIHA的发病机制、治疗方法做了简单总结,旨在为临床治疗提供指导。Autoimmune hemolytic anemia(AIHA)is a hemolytic anemia disease mediated by autoantibodies.The immune mechanism and regulatory function of the body are disrupted,and the effects of antibodies or/or complement on the red blood cell membrane cause damage to red blood cells,leading to hemolytic anemia.Most patients are sensitive to adrenal hormone response,and the treatment effect has significantly improved.But there are also some patients whose overall treatment effect is unsatisfactory due to their urgent onset,rapid progression of the disease,or strong hormone resistance.This study provides a brief summary of the pathogenesis and treatment methods of AIHA,aiming to provide guidance for clinical treatment.

关 键 词：自身免疫性溶血性贫血 治疗 发病机制 

分 类 号：R556.6[医药卫生—血液循环系统疾病]